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ABSTRACT
Objectives: To examine adherence to ADHD stimulant medications and determined the
condition-related, therapy-related, patient-related, health-system related, and social and
economic related predictors of medication nonadherence in children/adolescents (4 – 18 years)
with ADHD enrolled in Mississippi Medicaid Program.
Methods: This was a retrospective cohort study of the Mississippi Medicaid
administrative claims data. Data was analyzed from March 01, 2014 to February 29, 2016.
Adherence was calculated as the proportion of days covered (PDC). PDC was calculated
including and excluding summer break (June – August) and at two different timelines, at 6
months and 12 months depending upon the length of continuous enrollment of patients. PDC less
than 0.80 was considered nonadherent. Multivariable logistic regression model was constructed
to identify predictors of medication nonadherence.
Results: The study included 2,573 patients for PDC measure at 6 months, 58.88% were
between 6 – 11 years of age, 68.71% of them were male, and 48.74% Caucasian. 2,428 patients
for PDC measurement at 12 months were included. 59.23% were between 6 – 11 years of age,
68.29% of them were male, and 48.19% Caucasian. Including summer break, 67.24% of the
patients were nonadherent at 6 months and 41.52% at 12-month measurement. Excluding
summer break, 63.31% of the patients were nonadherent at 6 months and 43.45% at 12 months.
To identify predictors of medication nonadherence, the cohort for adherence measurement at 6
months including summer break was used. In an unadjusted analysis, patients having non-severe
ADHD, lack of follow-ups, using long-acting medications, having no psychiatric disorder, and
ii

between the age of 12 – 18 years were more likely to be nonadherent. Multivariable analysis
revealed lack of follow-ups, having non-severe ADHD, African-American race, and
geographical region – 5 as potential predictors of nonadherence to prescribed stimulant
medications.
Conclusion: In this study, adherence at 12 months was better than 6 months, and no
significant differences in adherence was observed after including and excluding summer break.
Significant predictors of nonadherence included lack of follow-ups, having non-severe ADHD,
African-American race, and geographical region – 5. A proper understanding of these predictors
will help the development of interventions to improve the medication adherence among ADHD
patients.
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CHAPTER I: INTRODUCTION
Attention deficit hyperactivity disorder (ADHD) is a chronic neurological disorder and its
symptoms include inattention, hyperactivity, and impulsivity (Charach et al., 2011). Various
genetic and imaging studies have shown that symptoms of ADHD are mainly due to the
abnormalities found in the dopaminergic and noradrenergic transmitter systems of the brain,
which lead toward impaired neurotransmission (Biederman & Faraone, 2005; Banaschewski et
al., 2006). It is estimated that 5% of children suffer from ADHD across the world (Charach et al.,
2011). In 2011, 11% of children (4 – 17 years) were estimated to have been diagnosed with
ADHD in the United States (“Data and Statistics | ADHD | NCBDDD | CDC,” n.d.).
Pelham et al. (2007) estimated that mean annual total cost of illness (COI) for
children/adolescents with ADHD was $14,576 (2005 dollars) per individual. Assuming a 5%
prevalence rate of ADHD, the total aggregated annual COI for school-aged children in the
United States with ADHD was estimated to be $42.5 billion (Pelham, Foster, & Robb, 2007).
Stimulant and non-stimulant classes of medications are used to treat ADHD in children
(Pediatrics, 2001; Pliszka, 2007; NICE, 2008; Michelson et al., 2004). Stimulants such as
methylphenidate (MPH) and amphetamine are first-line medications. Various non-stimulants
such as atomoxetine, guanfacine, and clonidine are also used to treat ADHD (Sallee et al., 2009;
Pliszka, 2007). Despite the proven effectiveness of ADHD medications, research has shown that
adherence to these medications varies from 50 - 75% depending upon how adherence is
estimated (Hack & Chow, 2001). However, adherence to therapeutic regimen plays a vital role in
achieving therapeutic effectiveness and improving patient outcome (Horne, 1999; WHR, 2002).
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Nonadherence to medication can lead to various unwanted effects, such as worsening of
symptoms, increased use of physician services, unnecessary hospitalizations, and even mortality
(Milgrom et al., 1996; Kennard et al., 2004; Rapoff, 2009). Furthermore, nonadherence related to
ADHD medications can lead toward difficulties in assessing the need for medication changes
and determining treatment efficacy and titration issues (Lisa and Nierenberg, 2010).
Various researchers have identified factors which affect medication adherence. Some of
the general factors associated with medication nonadherence include current substance abuse,
low motivation to change in behavior, low socioeconomic status, a complexity of dosing
regimen, treatment side effects, and medication cost (TEC, 2003; Bender, 2002; Wilson, 2003;
Bartlett, 2002). Factors associated with nonadherence in ADHD management include the type of
medication (long-acting vs. short-acting), treatment ineffectiveness, side effects, older age,
family history of ADHD, lower intelligence, and male gender (Ahmed and Aslani, 2013;
Firestone, 1982).
Numerous studies have evaluated medication adherence. Most of the studies on
predictors of medication adherence in ADHD have used self-report, parent report, clinical
interviews, or clinical trials to estimate adherence and identify predictors with smaller sample
sizes. Using these methodologies may overestimate the actual adherence rate (Hong et al., 2013;
Thiruchelvam, Charach, & Schachar, 2001; Gau et al., 2006; Sobanski et al., 2014; Faraone et
al., 2007; Atzori P et al., 2009; Sitholey, Agarwal, & Chamoli, 2011) Moreover, we know that
there are problems associated with small sample sizes in studies, for example, small sample sizes
can lead to wider confidence intervals, which will ultimately lead toward imprecise estimation of
the effect and no firm conclusion can be drawn from the study.
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Also, there are various studies in which medication utilization patterns and medication
adherence in ADHD have been estimated using administrative claims data, but only one study
has reported predictors of medication nonadherence in children and adolescents with ADHD. In
a study conducted in the Texas Medicaid population, medication possession ratio was calculated
to measure adherence using prescription claims data. The authors identified predictors of
medication nonadherence in ADHD and concluded that low adherence was due to older age,
male gender, and frequent dosing of medications (Barner, Khoza, and Oladapo, 2011).
However, this study has not used any framework to guide the identification and inclusion
of predictors contributing to medication nonadherence in children with ADHD providing an
incomplete picture of predictors of medication nonadherence. For the current study, the World
Health Organization (WHO)’s five dimensions of adherence will be used as a theoretical
framework to identify predictors of medication nonadherence using administrative claims data
from the Mississippi Medicaid program. With the help of this framework, factors contributing in
all dimensions of nonadherence will be assessed in this study.
Medicaid plays an integral role in United States healthcare system. Medicaid provides
health coverage for millions who lack access to the private insurance system that covers most
Americans. Medicaid covers a broad group of the low-income population, including pregnant
women, children and some parents including working and jobless families, children, and adults
with various physical and mental health conditions and disabilities. Medicaid together with
Children’s health insurance program (CHIP) covers more than 1 in 3 low-income adults and
more than 50% of all low-income children (The Kaiser Commission on Medicaid and Medicare,
2010). Medicaid beneficiaries differ in demographic and clinical characteristics from the general
population (Lawson, Johnsrud, Hodgkins, Sasané, and Crismon, 2012). Therefore, studies are
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needed to identify predictors of medication nonadherence for ADHD medications in children and
adolescents enrolled in Medicaid so that better clinical decisions can be made to control the longterm negative consequences of ADHD and lower the economic burden caused by increased
usage of resources associated with nonadherence.
Under these circumstances, the purpose of this study is to identify predictors of
medication nonadherence in ADHD in a Medicaid population using administrative claims data.
With this intention, the objectives of this study are to:
1. Estimate the adherence to ADHD stimulant medications in children/adolescents (4-18
years) enrolled in Mississippi Medicaid program.
2. Determine the health-system related, condition-related, socio-economic, therapy-related,
and patient-related predictors of medication nonadherence in children/adolescents (4-18
years) with ADHD enrolled in Mississippi Medicaid Program.
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CHAPTER II: LITERATURE REVIEW
ADHD Overview
Attention deficit hyperactivity disorder (ADHD) is a chronic neurological disorder and its
symptoms include inattention, hyperactivity, and impulsivity (Charach et al., 2011). Various
genetic and imaging studies have shown that symptoms of ADHD are mainly due to the
abnormalities found in the dopaminergic and noradrenergic transmitter systems of the brain,
which lead toward impaired neurotransmission (Biederman & Faraone, 2005; Banaschewski et
al., 2006). It is estimated that 5% of children suffer from ADHD across the world (Charach et al.,
2011). In 2011, 11% of children (4 – 17 years) were estimated to have been diagnosed with
ADHD in the United States (“Data and Statistics | ADHD | NCBDDD | CDC,” n.d.).
Disturbance in family relationships, child’s quality of life, social and academic activity
can be disturbed due to the ADHD symptoms (ASA, 2000). If left untreated, ADHD can persist
into adulthood (Spencer et al., 2007; BIEDERMAN et al., 1996). Research has shown that onehalf and two-thirds of children with ADHD persist ADHD into their adulthood (Adler and
Cohen, 2004). Consequences of untreated adult ADHD includes increased rates of sexually
transmitted disease, excess motor vehicle accidents, high rates of marital divorce and separation,
poor academic and occupational performance (Adler and Chua, 2002; Barkley, 1998). Not only
statistically significant but clinically meaningful results have shown that children with ADHD
are having significantly lower school grades, lower achievement scores, high rates of grade
retention, and high rates of school dropouts when compared with their non-ADHD peers
5

(Barkley, 2006; Loe and Feldman, 2007). As ADHD is most common with school-aged children,
teachers are often the first to detect the symptoms of the ADHD and refer children for further
evaluations by healthcare professionals (Sax and Kautz, 2003).
Various risk factors for ADHD have been identified in different studies including, but not
limited to male gender, younger age, low socio-economic status, obstetrics complication, and
psychosocial adversity (Biederman and Faraone, 2005). Comorbidities are common and most
patients with ADHD experience comorbidities such as learning disabilities, mood disorders,
language disabilities, and anxiety disorder (Taylor, Döpfner, & Sergeant, 2004; Wolraich, 2006;
Spencer, 2006).
The Economic Burden of ADHD
Overall, a prominent economic burden is associated with childhood ADHD. Based on the
published study, Pelham et al. (2007) estimated the mean annual total cost of illness (COI) for
children/adolescent with ADHD was $14,576 per individual with range estimates from $12,005
to $17,485. This total COI is a sum of costs associated with health and mental health ($2,636),
educational ($4,900), and crime and delinquency ($7,040). By using 5% prevalence rate, the total
aggregated annual cost of illness (COI) for school-aged children in the United States with ADHD
was estimated to be $42.5 billion (Pelham et al., 2007).
In the year 2000, the economic burden associated with ADHD in the United States was
$US 31.6 billion out of which $US 3.7 billion was related to productivity losses (Pelham et al.,
2007).
A case-control study with >30,000 adult participants in employer-based healthcare plans
revealed 2 times higher direct healthcare cost for ADHD versus non-ADHD control subjects
(Hodgkins et al., 2011).
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ADHD Treatment Recommendations
ADHD is a chronic disorder which in most of the patients requires long-term therapy
(Brown et al., 2005; NICE, 2008; Greydanus et al., 2007., Kessler et al., 2005). To improve the
ADHD symptoms and health-related quality of life of children, various therapeutic approaches
have been recommended including parent training, behavior therapy, educational interventions,
and pharmacological therapy (Taylor et al., 2004; Brown et al., 2005; NICE, 2008; Pediatrics,
2001).
Treatment recommendations by American Academy of Pediatrics (AAP) for ADHD
children vary according to the patient’s age:
1.

For pre-school aged children (4-5 years) clinician must prescribe evidence-based

parent and/or teacher administered behavior therapy as first-line and may prescribe
methylphenidate (MPH), if the behavior therapy doesn’t provide a significant improvement in
symptoms.
2.

For elementary-school aged children (6-11 years) clinician must prescribe US Food

and Drug Administration (FDA) approved medication for ADHD also behavior therapy and
preferably both should be used together.
3.

For adolescents (12- 18 years), the clinician must prescribe FDA approved

medication for ADHD with the agreement of a patient and may prescribe behavior therapy as
well and preferably both should be used together (Centers for Disease Control and Prevention,
n.d.)
According to the AAP medication for ADHD in children must start from low dose and
must be titrated according to the need of an individual (Taylor et al., 2004; NICE, 2008;
Pediatrics, 2001). Augmentation of medication is also recommended but only when first-line
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medications fail to achieve its therapeutic effect (AAP, 2001). Psychostimulants are the first-line
of medication in treating ADHD without comorbidity, but non-stimulants are also used to treat
the patient with ADHD (Pediatrics, 2001; Pliszka, 2007; AAP, 2001). Both are useful in treating
a patient with ADHD (NICE, 2008; Corkum & Rimer, 1999; Michelson et al., 2001; Michelson
et al., 2004).
Psychostimulants are currently available in three forms: short-acting stimulants (SAS) or
immediate release (IR) formulations (4 to 6 hours); intermediate-acting stimulants (IAS) or
sustained release (SR) formulations (6 to 8 hours); and long-acting stimulants (LAS) or
extended-release (ER) formulations (10 to 14 hours). SAS requires multiple dosing, and LAS are
once daily and more convenient as compared to other formulations. The Physician will need to
make the best choice of medication treatment for the children with ADHD. Physician’s choice is
based on a clinical condition of the patient, patient’s needs, and risk/benefit of the treatment.
In the United States, stimulant medications like methylphenidate (MPH) and
amphetamines are first-line of medications once pharmacological therapy started to treat ADHD.
Various non-stimulant medications are also used to treat ADHD some of which are atomoxetine,
a selective norepinephrine reuptake inhibitor which is considered first-line medication for
patients having comorbidity anxiety disorder, tics, or substance abuse disorders with ADHD
(Pliszka, 2007). Extended-release guanfacine (alpha-2A agonist) and clonidine are also used to
treat ADHD among the non-stimulant class of medications (Sallee et al., 2009).
Medication Adherence
Adherence is considered to be the primary factor for effectiveness of the treatment due to
the reason that poor adherence reduces the clinical outcome (Horne, 1999; WHR, 2002; Sarquis
et al., 1998). According to the World Health Organization adherence is “the extent to which a
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person’s behavior – taking medication, following a diet, and/or executing lifestyle changes,
corresponds with agreed recommendations from a healthcare provider” (World Health
Organization, 2003).
From this definition, one can understand that medication adherence is a multifaceted
behavioral process and factors such as an environment where people live and healthcare system
does play a role in determining overall adherence (ASA & ASCP, 2006).
Medication adherence is associated with how people understand about their disease, their
wish to manage it, ability to engage in disease management behaviors, expectation about the
outcome of the treatment, and consequences of nonadherence (World Health Organization,
2003).
The Problem of Medication Nonadherence
Research in different areas of medical and social sciences has concluded that half of the
patients in the United States do not follow or comply with their physician’s advice (DiMatteo,
1994; Shope, 1983; Shumaker et al., 1998). Statistics have shown that around 40% of the
patients take prescribed medication incorrectly or not at all (Epstein and Cluss, 1982).
Nonadherence has been or can be the cause of physician and patient frustration, which further
can be the cause of incorrect diagnosis and unnecessary treatment (Joshi & Milfred, 1995).
Gearing et al. (2011) proposed a model of when nonadherence occurs. He noted that
nonadherence to long-term therapies could occur early in the medication initiation process (e.g.,
a prescription is only filled), in the middle (e.g., completion of titration trial), or during the
maintenance phase of the treatment (Gearing et al., 2011). The causes of each type according to
the model can differ for the nonadherence.
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Adherence to medication regimen has always been a primary issue for the positive
outcome and even in developed countries average adherence to medications has been found only
at 50% for most chronic diseases, and now nonadherence is one of the public health issues
(World Health Organization, 2003; Lehane & Mccarthy, 2009). Worsening of symptom disorder,
mortality, physician visits, and unnecessary hospitalizations have been seen as consequences of
nonadherence to the medications (Milgrom et al., 1996; Kennard et al., 2004; Rapoff, 2009).
Adherence to medication has been observed to show improvement in overall quality of life
(Drotar et al., 2007; Ekberg et al., 2007; Fredericks et al., 2008; Hommel et al., 2008).
Charach’s (2004) evaluation of adherence on outcome in 79 patients with ADHD showed
better improvement in teacher-reported symptoms in patients who are adherent as compared to
the nonadherent patients. These ADHD patients were followed for five years after completion of
12 months randomized control trials (RCTs) (Charach et al., 2004).
Medication adherence related to chronic diseases have been identified as having a crucial
role in predicting mortality and morbidity. The diversion from physician’s advice or preferred
regimens can lead to the range of various unwanted effects (Clay et al., 2008; Krueger et al.,
2005; KB, AM, MW, Clay, & JN, 2003; Rapoff, 1999). Furthermore, the undesired therapeutic
outcome, poor adherence can also increase the economic burden of diseases (Buckley, 2009;
Osterberg, 2005). A waste of 300 billion dollars annually has been estimated in U.S health care
system only if the patients are not adherent to the medical therapy (Bender & Rand, 2004).
In addition to the unwanted effects, increase in healthcare utilization, and economic
burden the consequences for medication nonadherence in ADHD are not limited to the poor
outcome, but difficulties in assessing the need for medication changes, detecting treatment
efficacy, and titration may also arise for the health care provider, which in total will affect the
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treatment (Lisa & Nierenberg, 2010). Because ADHD can persist into adulthood and can lead to
negative consequences, following the clinician’s recommendation is an important factor for the
successful treatment (Spencer et al., 2007; Biederman et al., 1996).
Method to Measure Medication Adherence
Medication adherence can be measured through different approaches depending upon the need
and suitability of the research study. Some of the methods are discussed below:
Direct methods.
Biological Assays. Direct methods include the measurement of the drug
metabolite in body fluids, such as blood, urine, or saliva and assessment of the presence of a
biological marker given with the drug and direct observation of patient’s medication-taking
behavior. Direct measures are considered the most accurate in providing evidence that patient
has taken medication, but some drawbacks are associated with direct methods. For example,
direct measures only provide Yes/No pattern without giving any pattern of nonadherence or their
cause. Also, drug metabolism should be monitored as well. Additionally, interactions such as
drug or food can disturb the assay’s accuracy. Direct measures are very burdensome and costly
as well (Farmer, 1999).
Indirect methods.
Pill counts. This method counts the number of dosage units that have been taken
between two scheduled appointments or clinical visits. The obtained number would then be
matched with the total number of units; the patient has received to calculate the adherence ratio.
(Farmer, 1999; Vik, Maxwell, & Hogan, 2004). Various limitations have been identified in pill
count measure for estimating medication adherence. Pill count is not feasible for nondiscrete
dosages or Pro re nata (prn) medication (Vik, Maxwell, & Hogan, 2004). Moreover,
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underestimation of the medication adherence can also occur in pill count approach. Furthermore,
cutoff value to differentiate adherent and nonadherent are generated randomly, which can lead
toward inconsistency in the estimation of adherence in patients (Farmer, 1999).
Patient or parent self-report/questionnaire. The use of a patient questionnaire is
an easy approach to measure the medication adherence. However, a limitation associated with
this measure is the overestimation of the medication adherence levels in a patient that can often
be encountered (Horne et al., 2005).
Electronic medication monitors. Electronic monitoring devices such as
medication event management system (MEMS) consist of a computer chip in its cap of the bottle
and can record the time and dates when bottle or container is opened. The information further
can be used for analysis after downloading it into the computer. It must be noted that if patient
removed entire daily dose at one time rather than opening the bottle in its actual time can give an
inaccurate measure of adherence. Still, this method is considered more accurate, but electronic
monitors are not used often due to the cost issues (Ahmed & Aslani, 2013; Knafl, Schoenthaler,
& Ogedegbe, 2012).
Medication adherence measures for secondary database analysis. Here, identification
of medication adherence involves the examination of administrative data claims, which provides
the information on how many time refill of the prescription has been done (Ahmad and Aslani,
2013). There are few types of medication adherence measures used for claims analysis. Few of
them are discussed below:
Medication possession ratio (MPR). Medication or drug possession ratio
(MPR/DPR) is an outcome measure (Steiner & Prochazka, 1997). MPR is calculated as the total
number of days’ medication supply issued to the patient divided by the number of days’ patient
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should have been taking the medication. Andrade et al. (2006) defined MPR as the proportion (or
percentage) of the days’ supply obtained over either refill interval, where the last refill is the end
point, or fixed refill, where the particular period is set (Andrade, Kahler, Frech, & Chan, 2006).
Proportion of days covered (PDC). The proportion of days covered (PDC) is also
used to measure the medication adherence, and most of the studies are commonly using this
method (Benner et al., 2002, 2004, & 2005; Chapman et al., 2005; J.A., W.C., & E.H., 2005).
The PDC is calculated as the number of days with drug on-hand divided by the number of days
in the specified time interval. A percentage can be obtained by multiplying by 100. PDC always
a value between 0 and 1. PDC can be treated as a continuous or a dichotomous variable.
Dichotomous variable. In this measure, adherents and nonadherents, or partial
adherents are separated with the help of a cut-off value. This measure is considered to have low
sensitivity due to lack of pharmacological basis for cut-off values (Farmer, 1999; Steiner &
Prochazka, 1997).
Continuous, multiple interval measure of medication acquisition (CMA). CMA
is assessed as the cumulative days’ supply obtained over a series of intervals divided by the total
number of days from the beginning to the end of the period in a study. The overall average of all
participants’ CMA provides is the adherence value of the entire period of the study (Steiner &
Prochazka, 1997; Hess, Raebel, Conner, & Malone, 2006).
Continuous, multiple interval measure of medication gaps (CMG). CMG
measures are assessed by dividing the total number of days in treatment gaps and the duration of
the period to identify any time intervals without drug exposure. (Steiner & Prochazka, 1997).
Continuous, single interval measure of medication acquisition (CSA). CSA is
calculated by the days’ supply obtained in each interval over the total days in the interval
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(Steiner & Prochazka, 1997).
Continuous, single interval measure of medication gaps (CSG). CSG is
calculated by the number of days without any medication divided by the number of days in the
interval. Like CSA, CSG is better for short-term drug usage, such as patients having only one
prescription and the short drug usage is related to clinical outcome (Steiner & Prochazka, 1997).
Table 1. Equations of medication adherence measures involving secondary database analysis and pill count
(Farmer, 1999; Vik et al., 2004; Steiner and Prochazka, 1997; Hess et al., 2006; Benner et al., 2002, 2004, & 2005;
Chapman et al., 2005; J.A., W.C., & E.H., 2005).

Measures
Medication Possession Ratio(MPR)
Proportion of days covered (PDC)
Dichotomous variable
Continuous, Multiple Interval Measure
of Medication Acquisition (CMA)
Continuous, Multiple Interval Measure
of Medication Gaps (CMG)
Continuous, Single Interval Measure of
Medication Acquisition (CSA)
Continuous, Single Interval Measure of
Medication Gaps (CSG)
Pill count

Medication adherence equations
Days’ supply obtained/refill interval or fixed interval
Number of days with drug/number of days in the specified
time interval
N/A (arbitrary cutoff value)
Cumulative days’ supply obtained over a series of
intervals/total days from the beginning to the end of the time
period
Cumulative days without any medication over a series of
intervals/total days from the beginning to the end of the time
period
Days’ supply obtained in each interval/total days in the
interval
Number of days without any medication/total days in the
interval
(Number of dosage units dispensed − number of dosage units
remained)/ (prescribed number of dosage unit per day Å~
number of days between 2 visits)

Medication Adherence of ADHD Medications
Considering the ADHD medication usage, estimates of adherence ranges from 50 - 75%
depending upon how adherence has been calculated (Hack & Chow, 2001). Approximately, 50%
of the children advised to take ADHD medication only fill their prescription once or first only
(Olfson et al., 2003). Various methods are available to measure medication. Likewise, medication
adherence of ADHD in children is also evaluated considering various methodology in the previous
literature.
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Evaluation of ADHD medication adherence in literature. Pappadopulos et al. (2009)
has shown in his MTA study for evaluating medication adherence in salivary samples that only
50% of participant assigned medication and combined treatment groups were adherent
(Pappadopulos et al., 2009). A study conducted by Hong et al. (2013) estimated that prevalence
of nonadherence rates in a one-year observational study was found to be 35.5% in the newly
diagnosed children and adolescent with ADHD, and 64.5% were adherent in a total sample
(n=860). Adherence to ADHD medication was then assessed by the treating physician using
information obtained during the interview. Six groups were used to categorize: prescribed
medication was taken (1) never, (2) occasionally, (3) some of the time, (4) most of the time, (5)
always, and (6) not applicable. Later the patients were categorized into adherent and nonadherent
groups (Hong et al., 2013).
A study conducted by Charach et al. (2004) estimated adherence on 79 children
previously enrolled in RCT of MPH and parent treatment groups. Adherence was measured
through parent and child interview and by pill count. Adherence was defined as taking
medications ≥ 5 days a week with no more than 14 weeks a total per year of holidays. Adherence
decreased over the years gradually. At year 2, 53%, year 3, 44%, year 4, 38% and finally year 5,
36% of the patients were adherent to their medications (Charach et al., 2004).
Faraone et al. (2007) estimated adherence to OROS-MPH in a one-year study on a
sample of 407 children aged 6-13 years. Parent reports were used to measure adherence. A child
was considered adherent if the parent’s dosing records for each monthly visit indicated the child
had taken his medication ≥ 5 days a week except for planned medication holidays. Of 407
children only 289 (71%) of the participants completed this study. Mean adherence was found to
be 86.4% (Faraone et al., 2007).
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Gau et al. (2006) conducted a study on adherence of ADHD stimulant. In this study,
adherence was considered “good” and “poor.” “Poor” was defined if pills missed >14 days in a
whole month. Approximately 74% were found to be adherent “good” in a total sample (n= 307)
(Gau et al., 2006). In another observational study on a sample from Taiwan, poor adherence was
defined as an omission of ≥1 dose on school days on ≥2 days/week for 4 weeks and concluded
the results as 60.5% of patients’ adherent to their medication (Gau et al., 2008).
Here, one important point to consider is that it is not clear how far parents or a child can
accurately think back onto the past events and report the medication use. Additionally, it is
difficult for parents and patients to report their medication use regularly on daily or weekly basis
suppose in a five-year study.
Therefore, retrospective estimation of adherence has also been conducted by few authors.
Perwien et al. (2004) conducted a study on pharmacy claims to assess adherence via Medication
possession ratio (MPR) considering >80% adherent. The results concluded that 70% were
adherent after 30 days, between 60 -120 days only less than 15% were adherent, between 121 –
270 days only 5% were left adherent of the total sample (n=735) (Perwien et al., 2004).
Barner et al. (2011) conducted a study among Texas Medicaid children. Adherence
estimated via MPR. Poor adherence found as a result with mean 37.2% to 52.5%. After
dichotomizing using 80% cut-off, adherence among medication type (non-stimulant, ERstimulant, Prodrug stimulant, and IR-stimulant) ranged from 9.8 – 25.8% (Barner et al., 2011).
Predictors of Medication Adherence in ADHD
Various predictors of medication adherence and nonadherence have been reported by
different researchers for ADHD medications in children in different prospective and
retrospective studies. Due to the complex nature of the phenomenon, medication adherence can
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be affected by the patient, healthcare provider, care delivery system, supportive environment of
the patient (Miller et al., 1997). Some of the specific barriers reported by the researchers to
medication adherence are current substance abuse, low motivation to change in behavior, lowsocioeconomic status, a complexity of dosing regimen, treatment side effects, and medication
cost (TEC, 2003; Bruce G. Bender, 2002; Wilson, 2003; Bartlett, 2002).
Factors increasing medication adherence in children with ADHD. Researchers have
documented one of the significant predictors, which enhances the medication adherence is the
presence of comorbidities and medications used to treat them (S.R. et al., 2012; Atzori et al.,
2009). This could be justified because additional psychotropic medication might not only help in
curing symptoms of comorbid conditions, but also ADHD symptom management. The need for
multiple medications may be due to the reason of the severity of ADHD. Hence, to make the
treatment and symptoms better additional medication would enhance utilization pattern.
Researchers have also documented that children living in foster care and children living
with separated parents are also the predictors of increased medication adherence/persistence.
Greater adherence/persistence in children residing in a foster family maybe due to the reason of
proper monitoring and management of the child’s therapy done by foster parents (S.R. et al.,
2012; Atzori et al., 2009). For children living with separated parents, educational and behavioral
approaches for therapy management might be difficult for the parents collectively, which leave
them no other option than focusing on medication therapy and hence, could be the reason for
increased adherence (Atzori et al., 2009).
A study conducted by Barner et al. (2011) identified factors associated with increased
medication adherence were females, increase in the total number of medications, and comorbid
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medications. Medication adherence was estimated through medication possession ratio (MPR)
(Barner et al., 2011).
Factors contributing to poor medication adherence in children with ADHD. One of
the systematic reviews conducted by Ahmed and Aslani (2013) has reported different studies
identified different predictors of medication adherence and nonadherence. One of the noticeable
predictors of poor adherence is the type of medication based on duration (whether medication is
long acting or short acting) identified in 13 studies. Long-acting medication are associated with
better medication adherence, and short-acting medications are related to poor medication
adherence regardless of stimulant or non-stimulant drug class (Gau et al., 2006; Chou et al; 2009;
Tzang et al., 2012; Rothenberger et al., 2011; Adler et al., 2011; Ramos-Quiroga et al., 2008;
Spencer et al., 2011; Wong et al., 2009; S.R. et al., 2012; Christensen et al., 2010; Lachaine et
al., 2012; Lawson et al., 2012). Long-acting medication decreases the chances of forgetfulness as
they are administered once daily to the patients. Hence, patient convenience and adherence will
increase (Gau et al., 2008). Short-acting medications will need to be administered multiple times
based on patient needs. Hence, SA medications are predicted as one of the factors for poor
adherence (Gau et al., 2008; Wong et al., 2009).
Treatment ineffectiveness is another predictor of poor adherence, having no symptomatic
improvement in the patient’s symptoms lead to treatment discontinuation. Higher doses are also
found to be one of the predictors of poor adherence (Gau et al., 2008). Treatment side effect is
also one of the most noticeable predictors of medication nonadherence, which may also be due to
higher doses as well (Wong et al., 2009). Children with ADHD can experience different adverse
effects with both classes of ADHD medication, stimulant, and non-stimulant, these adverse
effects can impact the adherence rates (Swanson, 2003; Graham & Coghill, 2008). Side effects
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related to stimulant medication are decreased appetite, weight loss, insomnia, and headaches
(Gibson et al., 2006; Wolraich et al., 2007) Common side effects of atomoxetine; a non-stimulant
are gastrointestinal upset, low appetite, and sedation (Eli Lilly and Company, 2010).
Age has also been found to be one of the predictors of medication nonadherence. Patients
diagnosed at a younger age are more likely to be adherent as compared to the patients treated at
an older age. At younger age parent of the patients are more responsible for child’s therapy and
as the child grows in his age the management of the treatment and responsibility of the parents’
decreases and shifts toward the patient himself (Gau et al., 2008; Lawson et al., 2012; Atzori et
al., 2009; McCarthy et al., 2012).
Children having a family history of ADHD and a higher level of parental education are
the predictors of poor medication adherence reported by the researchers as well. It has been
suggested that family history with ADHD may cause less monitoring in children due to poor
management skill with ADHD and poor adherence may result. The reasons for the association
between higher level of education and poor medication adherence could not be concluded, and
further study is suggested by the author (Gau et al., 2008).
Different authors also report various other predictors in different studies. Firestone (1982)
has reported lower intelligence and male gender as predictors of poor medication adherence in
his study on factors associated with children’s adherence to stimulant medications (Firestone,
1982). Thiruchelvam et al. (2001) has reported oppositional defiant symptoms (ODD) as a
predictor of poor medication adherence, where the author has indicated that children with ODD
were 11 times more inclined to suspend the treatment as compared to those without ODD
(Thiruchelvam et al., 2001).
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A retrospective analysis conducted by Christensen et al. (2010) of ADHD medication
users for age 6 or older assessed medication adherence and persistence. Medical data, pharmacy
data, and enrollment information were used to examine treatment pattern. Medication adherence
and persistence were found to be significantly (P< 0.0001) greater in patients on stimulant vs.
non-stimulant (57% vs. 49%; 252. days vs. 154.3 days). Adherence and persistence were higher
for long-acting medications vs. short and intermediate acting medications (Christensen et al.,
2010) Similarly, another retrospective analysis conducted by Barner et al. (2011) revealed
frequent dosing, male gender, and older age were associated with the lower adherence rates in
children enrolled in Texas Medicaid (Barner et al., 2011).
Purpose of the Study
The purpose of identifying predictors of medication nonadherence is to provide the best
possible care to the children with ADHD. Numerous studies have evaluated medication
adherence. Most of the studies on predictors of medication adherence in ADHD have used selfreport, parent report, clinical interviews, or clinical trials to estimate adherence and identify
predictors with smaller sample sizes. Using these methodologies may overestimate actual
adherence rates. These authors have reported their methods to assess adherence as their
limitation as well. For example; Hong et al. (2013) reported physician clinical judgment for
assessment adherence as a limitation. Thiruchelvam et al. (2001) reported determining adherence
from self-report can be unreliable. Gau et al. (2006) reported adherence rates might be
overestimated because of the parent report. Sobanski et al. (2014) reported randomized
controlled trials setting, limiting extrapolation of the finding to routine clinical care. Faraone et
al. (2007) reported one of the limitations of a clinical trial, where high adherence may have been
because of monthly contact with investigators. Atzori P. (2009) and Sitholey P et al., (2011)
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reported small sample sizes as a limitation for the generalizability. According to Pappadopulos
(2009), Wagner and Rabkin (2000) source of the evidence does have an impact on the estimation
of the adherence (Pappadopulos et al., 2009; Wagner and Rabkin, 2000)
Moreover, we know there are problems associated with small sample sizes in studies, for
example, small sample size can lead to the wider confidence interval, which ultimately will lead
toward imprecise estimation of the effect and no firm conclusion can be drawn from the study.
Studies with large sample sizes produce narrow confidence intervals and therefore, more precise
results. Another limitation of the small sample size is that it can produce false positive results
(Hackshaw, 2008). Therefore, the sample size must be large enough for the study to have
sufficient statistical power to detect the differences deemed essential (Bonita, Beaglehole, and
Kjellström, 2006).
However, there are various studies in which medication utilization and medication
adherence in ADHD have been estimated using administrative claims data, but only one study
has reported predictors of medication nonadherence in children and adolescents with ADHD. A
study conducted in the Texas Medicaid population. Data extracted from July 2002 – December
2008. Medication possession ratio was calculated to measure adherence using prescription claims
data. Adherence was used continuously and dichotomously. A total of 62,789 beneficiaries were
studied for adherence, persistence, and cost. Patients included in the study were 3 – 18 years of
age; prescribed at least two prescription claims of the index medication; continuously enrolled
for 6 months before and 12 months following the index date. The authors concluded that low
adherence was due to older age, male gender, and frequent dosing of medications. (Barner,
Khoza, and Oladapo, 2011). However, this study has not used any framework to guide the
identification and inclusion of predictors contributing to medication nonadherence in children
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with ADHD, providing an incomplete picture of predictors of medication nonadherence. Also,
this study did not use ICD codes to identify patients based on their ADHD diagnosis rather
prescription claims were used as proxies for disease states.
Medicaid plays an integral role in United States healthcare system. Medicaid provides
coverage for millions who lack access to the private insurance system that covers most
Americans. Medicaid covers a broad group of low-income populations, including pregnant
women, children and some parents including working and jobless families, children, and adults
with various physical and mental health conditions and disabilities. Medicaid together with
Children’s health insurance program (CHIP) covers more than 1 in 3 low-income adults and
more than 50% of all low-income children (The Kaiser Commission on Medicaid and Medicare,
2010). Medicaid population does differ in demographic and clinical characteristics from the
general population (Lawson et al., 2012).
This study intends to use WHO’s five dimensions of adherence as its theoretical
framework and will identify predictors reported in the previous literature which then will be used
for each dimension of adherence to see whether these factors does influence adherence in
Medicaid population or no. Coupled with WHO’s framework, rates of adherence, and identifying
predictors of medication nonadherence in a recent Medicaid dataset will add a significant study
to the research area of ADHD in Medicaid population. Furthermore, the fact that Medicaid is an
integral part of the U.S healthcare system; the results of this study will help physicians/clinicians
to make better evidence-based clinical decisions for ADHD children in Medicaid population. So
that long-term negative consequences of ADHD and economic burden caused by increased usage
of resources associated with nonadherence could be controlled.
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As enhancing the effectiveness of adherence interventions might have a better impact on
the overall health of the patients than any improvement in specific medical treatments (Haynes et
al., 2001).
Due to such significance of the study and to achieve the above-mentioned purpose, the
specific objectives of the study are to:
1. Estimate the adherence to ADHD stimulant medication in children/adolescents (4 – 18
years) enrolled in Mississippi Medicaid program.
2. Determine the health-system related, condition related, socio-economic, therapy-related,
and patient-related predictors of medication nonadherence in children/adolescents (4 – 18
years) with ADHD enrolled in Mississippi Medicaid Program.
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CHAPTER III: THEORETICAL FRAMEWORK
To identify the predictors of medication nonadherence in children, World Health
Organization’s five dimensions of adherence was used as a theoretical framework. Predictors
either reported in previous literature, WHO’s framework and more importantly if they were
available in Mississippi Medicaid dataset were used for each dimension of the framework. Hence,
according to the WHO report long-term adherence: Evidence for action; it is entirely misleading
and not correct if only patients are held responsible for their adherence to medication because
medication adherence is a multidimensional phenomenon where five different types of dimensions
play their role in determining overall adherence (World Health Organization, 2003).
WHO’s five dimensions are following:
Figure 1. Five dimensions affecting medication
adherence

a)

Condition-related factors.

b)

Therapy-related factors.

c)

Patient related factors.

d)

Healthcare team and system related
factors.

e)

Social and economic factors.
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Once the factors leading toward medication nonadherence identified, then proper
interventions can be achieved for each factor to overcome the medication nonadherence (Lam &
Fresco, 2015).
Some of the factors reported by WHO are mentioned below:
Condition-related factors
In WHO’s report following condition-related factors are reported: Severity of symptoms,
a level of disability (Physical, psychological, social, and vocational), the rate of progression, the
severity of disease, and the availability of effective treatments are considered few factors which
influence the patient’s adherence. Comorbidities are also deemed to be a prominent influencer of
adherence in patients (Ciechanowski et al., 2000).
Therapy-related factors
There are various therapy related factors considered to influence the adherence. Some of
them are related to the duration of treatment, frequent changes in treatment, previous treatment
failure, side effects and the availability of medical support to deal with them.
Patient-related factors
Some of the main patient-related factors supposed to influence the adherence are
forgetfulness; mental stress; fear about the side effects; insufficient knowledge and skill in
managing the disease symptom and treatment; the complexity of drug regimen; low attendance at
follow-up, at counseling, motivational, behavioral, or psychotherapy classes. Additionally,
negative beliefs regarding the efficacy of the treatment, misunderstanding of therapy instruction
and non-acceptance of the disease; low treatment expectations; hopelessness and negative
feelings are also considered to be few factors to influence the medication adherence of the
patients.
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Healthcare team and system-related factors
Providers do play a prominent role in determining medication adherence, and it has been
reported that adherence may improve if the relationship between patient and provider is better
(Rose et al., 2000). There are several factors reported to influence adherence negatively. These
contain; poor health care services with insufficient or non-existent reimbursement by health care
insurance plans, inadequate medication delivery systems, lack of knowledge on managing
chronic diseases, short consultations, inability to establish self-management capacity, and lack of
knowledge on adherence and interventions for improving it.
Social and economic factors
Social and economic factors include poor socioeconomic status, illiteracy, low level of
education, unemployment unstable living conditions, long distance from the treatment center,
high-cost of transport, high cost of medication, changing environment situations, culture and lay
belief about illness and treatment, and family dysfunction.
The race has also been one of the predictors of medication adherence. Cultural
differences have also been the reason behind racial discriminations (Morgan & Watkins, 1988).
Age has also been reported to one of the factors to influence adherence, but as stated in the report
effect of age on adherence is inconsistent.
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CHAPTER IV: METHOD AND STUDY DESIGN
A retrospective cohort study of the Mississippi Medicaid claims database was conducted.
This study analyzed Medicaid beneficiary claims from March 01, 2014 to February 29, 2016.
The study obtained approval from the Institutional Review Board (IRB) at the University of
Mississippi.
Data Source
Medicaid is a state and federal program. The purpose of this program is to provide health
care services to eligible low-income populations. Mississippi Medicaid mainly provides health
care services to children, families having low-income, disables, and pregnant women. To acquire
these Medicaid benefits and services every individual must meet certain eligibility criteria. The
eligibility depends upon income, age, family size, and situation. The same factors determine the
kind of benefits for every individual e.g., full, reduced, or limited Medicaid benefits.
(“Mississippi division of Medicaid,” n.d.). According to the Mississippi Medicaid’s 2013 report,
644,504 Medicaid beneficiaries were enrolled in the program as of August 31, 2013 (“Annual
Report for Fiscal Year 2013,” n.d.).
The Mississippi Medicaid administrative claims database was used for this study. This
database contains a beneficiary master file, inpatient claims file, outpatient claims file, medical
claims file, and prescription claims file.
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The beneficiary master file contains enrollment information for all Medicaid
beneficiaries. This file contains demographic data (e.g., data of birth, gender, and race), basis of
eligibility, dual eligibility, insurance type, monthly enrollment status, and county of residence.
The inpatient claims file is a claim level file and contains information about complete
stay records for beneficiaries who used inpatient services including diagnoses (e.g., ICD-CM),
procedures codes (e.g., CPT), ED visits, discharge status, a length of stay, and payment amount.
The medical claims file is a claim level file and contains information related to officebased visits, diagnosis (e.g., ICD-CM), procedure codes (e.g., CPT) date of service, provider
type, and the amount paid. Claims in a medical file are generated from physician’s private
practice.
Outpatient claims file is a claim level file and provides information regarding hospital
outpatient visits, diagnosis codes (e.g., ICD-CM), procedure code (e.g., CPT), date of service,
and billing information. Claims in an outpatient file are generated in hospital settings.
The prescription claims file is also a claim level file and contains information related to
the prescription supplied such as date of medication supplied, quantity supplied, the number of
refills, number of days supplied, amount paid, and National Drug Code (NDC).
Below mentioned Mississippi Medicaid claim files were used to extract all the necessary
variables of the study.
1. Beneficiary master file: The variables that were acquired from the beneficiary master file
are birth date, gender, race/ethnicity, residency county/region, foster care status (COE:
003, 007, 026) and the beneficiary identification number (Bene ID). The bene IDs were
used to link all other variables from other records or data files into one file.
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2. Inpatient/outpatient/medical claim files: These files were used to identify ADHD
patients, follow-ups, provider type (PCP/MHS), presence of chronic physical and
psychiatric disorders in 6 months before and 6 months after the index date. Diagnosis
codes (e.g., ICD-9-CM) were used to identify the ADHD patients and chronic physical
and psychiatric disorders.
3. Prescription claims file: The prescription filled date, refills, refill gaps, NDC, days of
supply, quantity supplied, class of ADHD medications, and type of medications, were
acquired from this file.
Study Period and Study Population
The Mississippi Medicaid data from March 01, 2014 till February 29, 2016 was analyzed.
This study intended to identify patients with a newly started ADHD medication (Table 2) and
continuously enrolled in Mississippi Medicaid program for 12 months. Continuity of Medicaid
enrollment was determined by using monthly eligibility file. Patients were considered newly
started if they have not had any ADHD medication claim within 6 months prior to the index date
(pre-index period). The date of the first stimulant prescription fill was considered the index date.
The index dates between September 01, 2014 and February 28, 2015 (index period) were
included in the study (Figure 2). Patients with the primary or secondary International
Classification of Diseases, 9th Revision, Clinical Modification diagnosis codes of ADHD
(314.00, 314.01) were identified as having ADHD. Stimulant therapy (Table 2) was identified
using National Drug Code (NDC). Prescription claims were checked for duplicates and in a case
of any duplication, the only first record was retained.
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The study population consisted of children/adolescents with ADHD, who were enrolled
in Mississippi Medicaid program. In addition, patients were included in the study who met the
following eligibility criteria.
Inclusion criteria:
•

Children/adolescent were required to have 4 – 18 years of age at the start of the
study period (March 01, 2014).

•

Participants were continuously enrolled in Mississippi Medicaid program for 6
months before and 6 months after the index date.

•

Participants had at least one medical claim with the diagnosis of ADHD (primary or
secondary) based on ICD-9-CM codes (314.00, 314.01) within 30 days before or
after the index date.

•

Participants had their index dates during the index period (September 01, 2014 –
February 28, 2015), allowed the participant to have an equal period of observation
in pre-index and post-index period e.g., chronic physical disorder, the presence of
psychiatric disorders, and follow-ups (Figure 2).

•

Received at least three prescription fills with a total 90 days of supply for an
ADHD stimulant medication (Table 2) in any form during the post-index period.

Exclusion criteria:
•

To limit the patients to a newly started ADHD medication, recipients were
excluded from the study if there was any prescription claim filed for an ADHD
medication in a pre-index period.

•

Patients were excluded from the study, if they had missing data for date of service,
quantity of supply, and days of supply of stimulant medication.
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Figure 2. Patient Sample Timeline

The Rationale for Evaluating Adherence of Stimulants Only
The rationale for choosing stimulants (methylphenidate and amphetamine) for adherence
analysis was that stimulants are the main pharmacological treatment for ADHD in the United
States. Stimulants are prescribed to more than 80% of outpatients treated for ADHD (Olfson et
al., 2003). Moreover, methylphenidate and amphetamines are the most widely used prescription
stimulants approved by the US Food and Drug Administration (FDA) for the treatment of ADHD
(Lakhan & Kirchgessner, 2012).
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Table 2: Medication for ADHD

Generic
(Stimulants)
Methylphenidate

Short-acting
(Immediate Release)
SA methylphenidate
SA dexmethylphenidate

Amphetamine

Intermediate-acting
(Sustained Release)
IA methylphenidate

SA dextroamphetamine
SA dextroamphetamine/
amphetamine salts

IA amphetamine sulfate

Long-acting
(Extended Release)
LA methylphenidate
LA dexmethylphenidate
LA dextroamphetamine/
amphetamine salts
LA dextroamphetamine
prodrug

Study Measures
Measurement of medication adherence. Medication adherence was assessed only for
methylphenidate and amphetamine drugs in any form (Table 2) using NDC codes. Medication
adherence was calculated by using a proportion of days covered (PDC). PDC was measured as
“the total number of days with a drug on hand (available) divided by the number of days in the
specified time interval.” The PDC calculation was based on the fill dates and the days of supply
for each fill of a prescription.
Here, one point for calculating medication adherence for ADHD medications is very
important that children when not attending school might not take their medications by assuming
they might not need their medications. This point is supported by Faraone et al. (2007) who
reported in an analysis of adherence to OROS methylphenidate, in a 1 – year open label study
that 30.5% of the patients enrolled in the study took planned medication breaks during summer
holidays (Faraone, Biederman, & Zimmerman, 2007).
Due to this reason, in this analysis, two different types of PDCs were calculated: one
including summer break and one excluding a period of school summer break from June 1 to
August 30 to get a more precise estimation of adherence and understand the difference in
adherence rates considering the planned holidays of summer (Figure 5).
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Due to such reason, the denominator for one PDC (including summer break) was the
observation period and the denominator for second PDC (excluding summer break) was
observation period minus summer break.
Below criteria is set for measuring the adherence.
•

Medication adherence (PDC) for each patient was calculated at 6 month and 12 month
depending upon the duration of continuous enrollment in the Mississippi Medicaid
program with ADHD stimulant therapy starting from the index date. (Figure 4).

•

PDC was calculated for any patient switching stimulant medication from
methylphenidate to amphetamine in any form or vice versa (Table 2). PDC calculation
was stopped if any patient on stimulant therapy switched medication to non-stimulant
within first 6 months after the index date. If any patient switched stimulant to nonstimulant therapy after the first 6 months from the index date, then PDC was calculated
for up to 6 months.

•

Patient taking any two types of stimulant medications in combination, for example, one
long-acting as a maintenance dose and one short-acting on as needed basis (prn) then
possession array was estimated and adherence was calculated for one of the two
medications in possession.

•

Patient refilled the prescription before finishing the previous fill, the number of days were
counted for an early refill and adjusted by shifting forward to count those days in a refill
gap. Hence, patients were credited with the number of days.

•

Patients with the refill gap of ≥ 60 days were considered inconsistent.

•

Estimated PDC values for the adherence rates ranged from zero to one, although there is
no standard cut-off point to differentiate adherent from a non-adherent, in this analysis a
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cut-off point of 0.80 was used. PDC less than 0.80 was considered nonadherent, while PDC
equal and more than 0.80 was considered adherent. Percentages were reported in the
analysis by multiplying the values by 100 and less than 80% were considered nonadherent.

Figure 3. Proportion of days covered (PDC) equation including summer break

PDC =

S

Days with Drug available
PDC Observation Period

Figure 4. Proportion of days covered (PDC) equation excluding summer break

S Days with Drug available

PDC =

PDC Observation Period - Summer Break
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Patients

Figure 5. PDC timeline excluding summer break
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Predictors of medication nonadherence. Predictors mentioned below were assessed in
the study and were grouped based on the WHO’s theoretical framework and according to each
dimension of the medication adherence.
Condition-related predictors. The predictor under this category was the severity of
ADHD. Patients who were taking more than one class of medication for ADHD e.g., stimulant
and non-stimulant (atomoxetine, guanfacine, and clonidine) in combination were assumed to
have a severe ADHD as compared to the patients taking only one class of ADHD stimulant
medication.
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Therapy-related predictors. Physicians should monitor children with ADHD with a newly
start of ADHD therapy for dose adjustment and appropriate medication. As per the measures from
healthcare effectiveness data and information set (HEDIS) of 2015 version, there are two phases
of follow-up care visits for a patient with ADHD. In HEDIS measures, the age of the patient is
specified 6 – 12 years as of index prescription start date (IPSD). The first phase is known as the
initiation phase, patients (6 – 12 years) in this phase are required to have their first follow-up care
visit with a health care provider within one month of medication dispensed for ADHD.
The second phase is known as the continuation and maintenance phase (C & M). In this
phase, patients (6 – 12 years) who did not discontinue their medication and remained on therapy
for at least 210-days and fulfilled the requirement of first visit within one month of the dispensed
ADHD medication, those patients have at least two follow-up care visits with healthcare provider
within 270-days (9-months) after initiation phase is finished. (Period, Phase, & Episode, 2015).
The first predictor under this category was the ADHD follow-up care visits of ADHD
children. The follow-up visits were categorized into following three categories:
•

0 follow-up visit.

•

1 follow-up visit.

•

≥ 2 follow-up visit.

The follow-up visits were checked for a period 6 months from the index date. The second
predictor under this category was the type of medication (long-acting vs. intermediate acting vs.
short-acting vs. combination (SA + LA).
Patient-related predictors. Two patient-related predictors were evaluated in this study.
They were: presence of any psychiatric disorder and the presence of chronic physical conditions.
These conditions (psychiatric and chronic) were identified in a 6 month prior to the index date
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(pre-index period) and 6 months after the index date in a post-index period. These conditions
were identified by using ICD-9-CM (Appendix I & II).
Psychiatric disorders such as conduct disorders, bipolar disorder, major depressive
disorders, other anxiety disorders, and other psychoactive substance disorders were included in
the analysis. A previous study reported that children with the chronic physical condition are
more likely to have concomitant mental health disorder (Suryavanshi & Yang, 2016). Therefore,
the following chronic physical conditions were identified: juvenile rheumatoid arthritis, asthma,
epilepsy, diabetes mellitus, infantile cerebral palsy, spina bifida, congenital anomalies of the
heart, sickle-cell disease, cystic fibrosis, blindness or low vision, color or night blindness,
hearing loss, and common childhood cancers (Cadman et al., 1987).
Healthcare team and system-related predictors. The predictor under this category was
the provider type (mental health specialist (MHS) vs. non-mental health specialist). Patients were
categorized based on their provider type. Patients were classified under mental health specialist if
mental health specialist prescribed diagnosis and ADHD prescription. The rest of the patients
were categorized under non-mental health specialist category.
Social and economic predictors. The predictors under this category include the
following:
1. Age
Age was categorized into three categories based on their birth dates at the start of the
study period.
•

4 – 5 years (Pre-school aged children)

• 6 – 11 years (Elementary school aged children)
• 12 – 18 years (Adolescents)
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2. Gender
Male and Female gender were used.
3. Race
This analysis identified the following race:
•

Caucasian

•

African – American

•

Other

4. Foster care
•

Yes/No. Foster care enrollment was identified for each patient using COE
variable (003, 007, 021). Foster care enrollment for each patient was identified in
index month.

5. Geographical region: Geographical location can play a vital role in assessing healthcare
accessibility. Furthermore, accessibility may influence patient’s medication adherence.
All 82 counties in Mississippi were categorized into 9 regions. All regions and their
respective counties are mentioned in Appendix III.
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Table 3. Predictors of Medication Nonadherence

Predictors of Medication Nonadherence
Adherence Dimensions
Condition-related

Predictors
Severity of ADHD
Follow-up Visits
Type of Medication (SA, IA, LA, SA +
LA)
Presence of psychiatric disorders
Presence of chronic physical disorders

Variable Type
Categorical
Categorical

Healthcare team and systemrelated

Provider type (MHS vs. Non-MHS)

Categorical

Social and economic

Age
Gender
Race
Foster care
Geographical region

Categorical
Categorical
Categorical
Categorical
Categorical

Therapy-related
Patient-related

Categorical
Categorical
Categorical

PCP = Primary care provider; MHS = Mental health specialist; SA = Short-acting; IA = Intermediate acting; LA =
Long-acting

Statistical analysis. The relationships between medication nonadherence (i.e., PDC ≥
0.80 adherent; PDC < 0.80 nonadherent) and categorical variables were evaluated using chisquare X2 test. In multivariable analysis, a logistic regression model was constructed to assess the
association between medication nonadherence and predictors of medication nonadherence.
Adjusted odds ratios (OR) and 95% confidence intervals were reported for each independent
variable in the multivariable model. All analysis was performed using SAS, statistical analysis
software, version 9.4 (SAS Institute, NC).

Statistical model.
Adherence = Severity of ADHD (REF = 0) + follow-ups (REF = 0) + Type of medication (REF =
1) + Psychiatric disorder (REF = 0) + Chronic Physical disorder (REF = 0) + Provider type
(REF = 0) + Age (REF = 1) + Gender (REF = M) + Race (REF = 1) + Foster care (REF = 0) +
Geo. region (REF = 1)
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CHAPTER V: RESULTS
Patient Characteristics for 6-month PDC
During the period from March 01, 2015 till February 29, 2016, 2,573 patients with
ADHD met the inclusion criteria for 6-month PDC calculation. 19.24% of them (495/2573) were
at age 4 -5 years, 58.88% (1515/2573) were between 6 – 11 years of age and 21.88% (563/2573)
were between 12 – 18 years of age. 68.71% of them (1768/2573) were male, 48.74%
(1254/2573) were Caucasian, 47.45% (1221/2574) were African – American, and 3.81%
(98/2573) were in the other race category. Among them 18.97% (488/2573) were only shortacting ADHD stimulant users, 53.21% (1369/2573) were only long-acting ADHD stimulant
users, 27.83% (716/2573) were using a combination of short-acting and long-acting stimulants.
54 ADHD patients were only using intermediate-acting ADHD stimulant and were removed
from the analysis due to small sample size. Table 4 shows the characteristics of the study
population.

40

Table 4. Patient characteristics of the total study population for a 6-month PDC

Patient Characteristics

ADHD Patients with 6-month PDC, N (%)

Total

2573 (100%)

Age
4–5
6 – 11
12 – 18

495 (19.24)
1515 (58.88)
563 (21.88)

Gender
Male
Female

1768 (68.71)
805 (31.29)

Race
Caucasian

1254 (48.74)

African – American

1221 (47.45)

Other

98 (3.81)

Type of ADHD Medications
SA
LA
SA + LA (Combination)

488 (18.97)
1369 (53.21)
716 (27.83)

SA = Short-acting, LA = Long-acting

Patient Characteristics for 12-month PDC
During the period from March 01, 2015 till February 29, 2016, 2428 patients with ADHD
met the inclusion criteria for 12-month PDC calculation. 19.19% (466/2428) were at age 4 -5
years, 59.23% (1438/2428) were between 6 – 11 years of age and 21.58% (524/2428) were
between 12 – 18 years of age. 68.29% (1658/2428) were male. 48.19% (1170/2428) were
Caucasian, 48.19% (1170/2428) were African – American, and 3.62% (88/2428) were in the
other race category. Among them 18.95% (460/2428) were only short-acting ADHD stimulant
users, 53.01% (1287/2428) were only long-acting ADHD stimulant users, 28.05% (681/2428)
were using combination of short-acting and long-acting stimulants. Table 5 shows the
characteristics of the study population.
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Table 5. Patient characteristics of the total study population for a 12-month PDC

Patient Characteristics

ADHD Patients with 12-months PDC, N (%)

Total

2428 (100%)

Age
4–5
6 – 11
12 – 18

466 (19.19)
1438 (59.23)
524 (21.58)

Gender
Male
Female

1658 (68.29)
770 (31.71)

Race
Caucasian

1170 (48.19)

African – American

1170 (48.19)

Other

88 (3.62)

Type of ADHD Medications
SA
LA
SA + LA (Combination)

460 (18.95)
1287 (53.01)
681 (28.05)

SA = Short-acting, LA = Long-acting

Medication Adherence
Proportion of days covered (PDC) was measured in two different ways: one including
summer break and the other excluding summer break. Also, two different timelines were
considered for PDC calculation, that is, at 6-month and 12-month depending upon patients’
continuous Medicaid enrollment status.
Based on PDC calculations, when excluding summer break, 63.31% (1629/2573) of the
ADHD patients were found to be nonadherent at 6 month with PDC of 80% being used as the
cut-off value for ADHD medication adherence. Table 6 shows the overall adherence rates based
on 6-month PDC measurement. Similarly, 43.45% (1055/2428) of the ADHD patient were found
nonadherent at 12 month with PDC of 80% being the cut-off value for adherence. Table 7 shows
the overall adherence rates for 12-month adherence based on PDC excluding summer break.
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Table 6. PDC at 6 months excluding summer break

Adherence

Number of Patients (N)

Percentage (%)

Nonadherent

1629

63.31

Adherent

944

36.69

Total

2573

100

Nonadherence = PDC < 80%

Table 7. PDC at 12-months excluding summer break

Adherence

Number of Patients (N)

Percentage (%)

Nonadherent

1055

43.45

Adherent

1373

56.55

Total

2428

100

Nonadherence = PDC < 80%

For PDC calculations including summer break, overall, 67.24% (1730/2573) of the
ADHD patients were found nonadherent (PDC < 80%) at 6 months. Similarly, patients who were
continuously enrolled in the Mississippi Medicaid program for 12-months, 41.52% (1008/2428)
of the ADHD patients were found nonadherent (PDC < 80%) to ADHD stimulant medications at
12 months. Table 8 presents the overall adherence rates for 6-month adherence based on PDC
and
Table 9 presents the overall adherence rates for 12-month adherence based on PDC
including summer break.
Table 8. PDC at 6 months including summer break

Adherence

Number of Patients (N)

Percentage (%)

Nonadherent

1730

67.24

Adherent

843

32.76

Total

2573

100

Nonadherence = PDC < 80%
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Table 9. PDC at 12-months including summer break

Adherence

Number of Patients (N)

Percentage (%)

Nonadherent

1008

41.52

Adherent

1420

58.48

Total

2428

100

Nonadherence = PDC < 80%

Predictors of Medication Nonadherence
To identify predictors of medication nonadherence in this population, we used the cohort
that was used for adherence measurement at 6 months including summer break. In the unadjusted
analysis, we found that among patients with ADHD continuously enrolled for 6 months in the
Mississippi Medicaid Program, 70.24% of those who did not have severe ADHD were
nonadherent (p = <0.0001). Among patients having ≥ 2 follow-ups, 64.93% were nonadherent (p
= <0.0001). Among patients using long-acting medications, 71.51% of the patients were
nonadherent (p = <0.0001). Among patients who did not have any psychiatric disorder, 69.36%
were found nonadherent (p = 0.0037). 72.65% of the patients between the age of 12 – 18 years
were nonadherent (p = 0.002). Among African-Americans, 79.20% were nonadherent (p =
<0.0001). Table 10 shows the results of the unadjusted analysis for all the potential predictors
with medication nonadherence.
Table 10. Results of unadjusted association between potential predictors and medication nonadherence with 6month PDC

Patient Characteristics

Adherent

Nonadherent

P Value

Severity of ADHD
Severe

326 (39.00)

510 (61.00)

<0.0001

Not Severe

517 (29.76)

1220 (70.24)

Condition - related

Therapy - related
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Follow-up Visits
0
1
≥2

42 (20.19)
69 (24.82)
732 (35.07)

166 (79.81)
209 (75.18)
1355 (64.93)

<0.0001

Type of ADHD Medications
SA
LA

168 (34.43)
390 (28.49)

320 (65.57)
979 (71.51)

SA + LA (Combination)

285 (39.80)

431 (60.20)

357 (36.17)
486 (30.64)

630 (63.83)
1100 (69.36)

199 (33.28)

399 (66.72)

644 (32.61)

1331 (67.39)

Provider Type
Mental Health Specialist

224 (32.14)

473 (67.86)

Non-Mental Health Specialist

619 (33.00)

1257 (67.00)

Age
4-5
6 - 11
12 - 18

185 (37.37)
504 (33.27)
154 (27.35)

310 (62.63)
1011 (66.73)
409 (72.65)

0.002

Gender
Male
Female

576 (32.58)
267 (33.17)

1192 (67.42)
538 (66.83)

0.768

Race
Caucasian
African - American
Other

558 (44.50)
254 (20.80)
67 (68.37)

696 (55.50)
967 (79.20)
31 (31.63)

Foster Care
Yes
No

24 (36.36)
819 (32.67)

42 (63.64)
1688 (67.33)

0.5278

Geographical Region
Region 1
Region 2

92 (37.40)
102 (36.96)

154 (62.60)
174 (63.04)

0.0005

<0.0001

Patient - related
Presence of Psychiatric Disorder
Yes
No
Presence of Chronic Physical
Disorder
Yes
No

0.0037

0.7597

Healthcare team and system related

0.6803

Social and Economic

45

<0.0001

Region 3
Region 4
Region 5
Region 6
Region 7
Region 8

35 (25.18)
56 (32.75)
118 (24.28)
78 (37.14)
64 (35.96)
87 (31.64)

104 (74.82)
115 (67.25)
368 (75.72)
132 (62.86)
114 (64.04)
188 (68.36)

Region 9

174 (34.66)

328 (65.34)

Chi-Square Test p < 0.05, Nonadherence = PDC < 80%, SA = Short-acting, LA = Long-acting

Multivariable analysis to identify predictors of medication nonadherence.
Condition-related predictors. In a multivariable model, when adherence was measured at
6-month using PDC nonadherence with ADHD stimulant medication therapy (Table 2) was high
for patients who did not have severe ADHD. Therefore, ADHD severity as measured using class
of ADHD medication was significantly associated with medication nonadherence, that is, those
with non-severe ADHD were more likely to be nonadherent. For example, compared with severe
ADHD patients, non-severe ADHD patients were 29% more likely to be nonadherent to ADHD
stimulant medications (OR = 1.299; 95% CI, 1.070 – 1.576; P = 0.002).
Therapy-related predictors. Using a multivariable model, we found that lack of ADHD
follow-up care visits in first 6 months from the index date was significantly associated with
medication nonadherence. This is evidenced by our results showing that when compared with the
reference group (patients with 0 follow-up), patients with ≥ 2 follow-ups were 48% less likely to
be nonadherent (OR = 0.519; 95% CI, 0.359 – 0.752; P = 0.0005).
Patient-related predictors. When compared with reference group (patients without
psychiatric disorder) patients with a psychiatric disorder were 18% less likely to be nonadherent
(OR = 0.817; 95% CI, 0.674 – 0.990; P = 0.0389).
Social and Economic predictors. When compared with the reference group (Caucasian)
patients with African – American race was 2.169 times more likely to be nonadherent as
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compared to Caucasians (OR = 3.169; 95% CI, 2.598 – 3.866; P <0.001). Similarly, patients
from the other race group were 67% more likely to be nonadherent (OR = 1.677; 95% CI, 1.064
– 2.643; P = 0.0259). When the geographical region was examined as a predictor in the
multivariable model, we found that patients from the region - 5 were significantly more likely to
be nonadherent. Patients from region - 5, when compared with the reference group (region - 1)
were 53% more likely to be nonadherent (OR = 1.534; 95% CI, 1.075 – 2.188 P = 0.0182).
Region - 5 contained the following counties: Claiborne, Copiah, Hinds, Madison, Rankin,
Simpson, Sharkey, Issaquena, Warren, Yazoo (Appendix III). Region I include the following
counties: Coahoma, Desoto, Grenada, Panola, Quitman, Tate, Tallahatchie, Tunica, Yalobusha.
Other potential predictors were not statistically significantly associated with medication
nonadherence. Table 11 shows the adjusted association with medication nonadherence and
potential predictors.
Table 11. Multivariable logistic regression: adjusted association between potential predictors and medication
nonadherence when measured at 6-month using PDC

Patient Characteristics

Adjusted Odds
Ratio

95% Confidence Interval
(CI)

P Value

Condition - related
Severity of ADHD
Severe
Not Severe

Reference
1.299

1.070 - 1.576

0.0082

0.529 - 1.324
0.359 - 0.752

Reference
0.4466
0.0005

Therapy - related
Follow-up Visits
0
1
≥2

0.837
0.519

Type of ADHD Medications
SA
LA

1.19

0.926 - 1.531

Reference
0.1742

SA + LA (Combination)

0.854

0.659 - 1.106

0.231

Patient - related
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Presence of Psychiatric
Disorder
Yes
No
Presence of Chronic
Disorder
Yes

0.817

0.674 - 0.990

0.0389
Reference

1.007

0.816 - 1.243

0.9474

No

Reference

Healthcare team and system
- related
Provider Type
Mental Health Specialist

0.828

0.664 - 1.033

Non-Mental Health Specialist

0.0947
Reference

Social and Economic
Age
4-5
6 - 11
12 - 18
Gender
Male
Female
Race
Caucasian
African - American
Other
Foster Care
Yes
No

0.785 - 1.273
0.925 - 1.671

Reference
0.9957
0.1489

0.873 - 1.287

Reference
0.5578

3.169
1.677

2.598 - 3.866
1.064 - 2.643

Reference
<0.0001
0.0259

0.601

0.177 - 2.039

0.999
1.243

1.06

0.4143
Reference

Geographical Region
Region 1
Region 2
Region 3
Region 4
Region 5
Region 6
Region 7
Region 8

1.169
1.437
0.918
1.534
0.974
0.814
1.283

0.805 - 1.698
0.884 - 2.338
0.593 - 1.420
1.075 - 2.188
0.651 - 1.455
0.532 - 1.246
0.876 - 1.879

Reference
0.4123
0.1437
0.7004
0.0182
0.8967
0.343
0.2013

Region 9

1.174

0.839 - 1.641

0.3493

SA = Short-acting, LA = Long-acting
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CHAPTER VI: DISCUSSION
This retrospective analysis sought to identify predictors of medication nonadherence in
children with ADHD who were on stimulant therapy (methylphenidate and amphetamine) only
in a Medicaid population. The proportion of days covered (PDC) was used to estimate
medication adherence and PDC was calculated in two different ways including and excluding
school summer break (June – August) (Figure 5) and at two different timelines, e.g., at 6-month
and 12-month following the index date. The current study is unique in assessing medication
nonadherence considering summer break (excluding June – August) in PDC calculations. We
found that medication adherence results based on PDC measurements did not differ when
summer months were included or excluded. Including summer break, 67.24% (PDC < 80%) of
the patients were found to be nonadherent at 6 months, 41.52% (PDC < 80%) were nonadherent
at 12-month. When excluding summer break, 63.31% (PDC < 80%) were found to be
nonadherent at 6 months and 43.45% were nonadherent at 12-month (PDC < 80%).
Upon a thorough review of the literature, we found that no previous studies have
measured medication nonadherence excluding summer break using administrative claims data,
but summer holidays were considered in studies employing smaller sample sizes. For example,
Faraone et al. (2007) reported in an analysis of adherence to OROS methylphenidate, in a 1 –
year open label study that 30.5% (124/407) of patients reported a history of taking planned
medication breaks during summer holidays, 23.6% (96/407) reported taking breaks on weekends,
and 16% of the study participants reported taking medication breaks on both summer break and
weekends. Overall, they reported a mean adherence was found to be 86.4%, and it was reduced
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to 77.7% for the sub-group of patients who reported taking planned medication breaks.
Adherence was defined as the total number of days’ medication taken divided by total number of
days in study.
Our finding that medication adherence/nonadherence rates measured by PDC were
similar when summer months were included and excluded is consistent with the study by
Faraone et al. The notion that low adherence may be due to the possibility of taking planned
medication break in summer in children with ADHD is not supported by the results of this study.
When adherence at both 6-month and 12-month were examined, the percentage of
patients being nonadherent to their medication is higher for a 6-month measurement and lower
for 12-month measurement. This difference may be due to the possibility of ADHD symptom
improvement. The supportive evidence is found from a study conducted by Ahmed et al.
reporting that parents were motivated to continue their child’s treatment due to the positive
impact of therapy on child’s behavior. Some improvements were observed, e.g., the decrease in
hyperactivity and aggression, child’s academic performance, and social progress after treatment.
The study was conducted to understand the parents’ perspectives about factors influencing
adherence to pharmacotherapy for ADHD. Focus groups were carried out to identify factors
which affect parent’s decision on initiation, continuation, cessation of treatment for their children
(Ahmed, Borst, Wei, & Aslani, 2013).
Another possibility of the improvement of medication adherence (a decrease in
nonadherence at 12-month) may be the increase in the number of follow-ups after first 6 months.
This study measured follow-ups in first 6-months from the index date only and we did find that
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patients having ≥ 2 follow-ups were significantly more likely to be adherent. Hence, there is a
possibility that patients had more follow-ups after first 6 months from the index date, which
decreased the rate of nonadherence at 12-month.
Because adherence in different studies has been measured using different methodologies,
it is often difficult to make comparisons across studies. The nonadherence rate of 67.24% as
measured by PDC at 6-month of this study is not accurately the same but still consistent with
what was reported in previous studies (Hong et al. 2013; Sanchez et al. 2005; Barner et al. 2011).
One study assessed medication adherence by the treating physician using information
obtained during an interview among patients with ADHD in central Europe and East Asia
reported that 35.5% of children with newly diagnosed ADHD were nonadherent (Hong et al.
2013). Another retrospective study conducted in Texas Medicaid database evaluated medication
adherence for ADHD medications (e.g., immediate-release methylphenidate, extended-release
methylphenidate, and mixed amphetamine salts) in children. Medication possession ratio (MPR)
was measured by adding the number of days of supply divided by the number of days in the
treatment period. Medication adherence ranged from 69% for immediate-release
methylphenidate, 73% for mixed amphetamine salts, and 76% for extended-release
methylphenidate. (Sanchez, Crismon, Barner, Bettinger, & Wilson, 2005).
A study conducted by Barner et al. (2011) measured medication adherence of the
stimulant and nonstimulant medication using MPR (MPR of 80% was used as the cut-off point).
Depending upon the medication type of stimulant medication (Immediate-release and extendedrelease), medication adherence ranged from 9.8% - 24% (Barner et al. 2011).
When compared findings of this study with another study of adherence to ADHD
medications, antidepressants, and antipsychotics among children with Autism spectrum disorder,
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56% of patients were reported to be nonadherent to ADHD medications, 60% to antidepressants,
and 48% to antipsychotics. Medication adherence was measured using PDC (Logan et al., 2014).
It should be noted that the observation period of 6 month is used for analysis in this
study, but other studies have used longer period for measuring medication adherence. As
mentioned earlier, the prevalence of nonadherence of this study is higher as compared to the
studies conducted by Hong et al. 2013 and Sanchez et al. 2005 and slightly lower than the study
carried out by Barner et al. 2011.
For the identification of potential predictors of mediation nonadherence, this study only
considered adherence measurement at 6 months including summer break (67.24%). Logistic
regression analysis identified several potential predictors for a higher risk of medication
nonadherence among children with ADHD, these predictors are: lack of follow-ups, having nonsevere ADHD, African – American race, and geographical region.
The current study found that nonadherence was higher for patients who did not have
severe ADHD. The results of this study are consistent with the study conducted by Thiruchelvam
et al. (2001). He reported that adherent patients were 60% more likely than nonadherents to have
more teacher-rated ADHD symptoms and severity of ADHD was measured by the number of
teacher-rated symptoms. The current study determined the severity of ADHD based on the usage
of stimulants in combination with nonstimulant medication.
This study also found that patients having ≥ 2 follow-ups for ADHD were significantly
less likely to be nonadherent to their medication. To date, no previous published study has
analyzed the impact of follow-up care visit on medication nonadherence in patients with ADHD,
but this finding is in line with the healthcare effectiveness data and information set (HEDIS)
measures, which suggest that ADHD patients should have at least one follow-up within the first
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month of dispensed medication and three within 10 months. This study assessed follow-up care
visits within first 6 months from the index date, and it implies that having more follow-up care
visits does have a positive impact on overall medication adherence. Although there are a lot of
studies having been published regarding different interventions to enhance medication adherence
and studies have reported that primary care consultations are associated with greater medication
adherence (Kerse et al., 2004), the results of this study support that following HEDIS measures
in clinical settings will have a positive impact on medication adherence.
Patients having psychiatric disorder as a comorbidity were more likely to be adherent
(and less likely to be nonadherent). It is possible that patients with psychiatric comorbidities
need to take more medications to treat them and seeing physicians more often, and studies have
reported a positive association between pill burden and medication adherence (Shalansky, Levy,
Morand, & Marcotte, 2002; Sharkness & Snow, 1992). The finding of this study is consistent
with previous studies which have reported that a presence of comorbidities and medication used
to treat them enhance medication adherence.
Atzori et al. (2009) reported in a study using clinical records of 134 children and
adolescents and found that comorbidity was one of the factors associated with continuation of
therapy. Another study conducted by S.R. et al. (2012) reported that patients with concurrent use
of psychotropic medications were positively associated with the persistence of index stimulant
medications.
Lastly, patients with African – American race and other race categories, and patients
from geographical region - 5 were also significantly more likely to be nonadherent. Findings
from previous research have reported that likelihood of being adherent or persistent is higher for
patients from the white origin as compared to the African – Americans and Hispanics. One study
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found that African – American, Hispanics and Asian children were 39% more likely to quit
taking their medications than white children (Bokhari, Heiland, Levine, & Ray, 2008). S.R. et al.
reported that blacks and Hispanics has a constant lower persistence when compared with the
whites and other/unknown races. Reis et al. (2003) has reported that nonsatisfaction rate is higher
among parents of the nonwhite children who were on ADHD medications. A parental
misconception about their child’s medication could be a possible influential mechanism on
medication nonadherence among Africans and Hispanic children with ADHD (DosReis, S.,
Magno Zito, J., Safer, D.J., Soeken, K.L., Mitchell, J.W. Jr. & Ellwood, 2003).
Patients from a geographical region – 5 were also found more likely to be nonadherent as
compared to the patients from other geographic areas. Region – 5 contained the following
counties Claiborne, Copiah, Hinds, Madison, Rankin, Simpson, Sharkey, Issaquena, Warren,
Yazoo. The possible reason for patients being nonadherent from regions – 5 is the possibility of
patients being from African - American origin, who are less likely to be adherent and a
possibility of having inadequate access to Medicaid health service centers from this region.
Future studies should identify the possible reasons for medication nonadherence among African
– American race and patients of a specific geographic area in Mississippi. Interventions should
be developed to help patients and improve medication adherence among these patients.
Surprisingly, the finding of this study did not reveal any significant associations of age,
gender and type of medication (LA, SA, and SA + LA) with medication nonadherence in the
multivariable logistic regression. Although previous studies have shown significant results,
Barner et al., 2011 revealed that older patients were associated with lower adherence. A
systematic review of 13 studies conducted by Ahmed and Aslani (2013) reported that type of
medication is a prominent predictor of medication adherence. Where long-acting medications
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were associated with better medication adherence and short-acting medications were related to
poor adherence. Different methodologies used in different studies may help explain these
disparities.
This study has several strengths. First of all, in order to examine medication adherence
from multiple perspectives, this study employed the WHO theoretical framework in identifying
predictors of medication adherence (nonadherence). Secondly, this study is the first one to
consider summer break in assessing medication nonadherence in observational studies using
administrative claims data. Our results show that medication holidays during summer break is
not a significant issue for medication adherence. Children/adolescents with ADHD did not stop
their medications during summer time when school is out. Therefore, any strategy to improve
medication adherence among children/adolescents with ADHD should emphasize throughout the
treatment course. And finally, we employed a stringent criterion categorizing children as having
ADHD, that is, children must have at least one ICD-9-CM codes for ADHD within 30-days
before or after the index date in order to be considered of having ADHD.
As very limited information is available regarding the predictors of medication
nonadherence among children with ADHD enrolled in Medicaid programs, findings from the
current study will add to the body of literature in this regard; future studies may utilize other data
sets or national Medicaid data to identify predictors of medication nonadherence among patients
with ADHD. The findings of this study may assist healthcare providers in identifying ADHD
patients at a higher risk to be nonadherent to ADHD stimulant medications, and interventions
designed to improve medication adherence should be employed to target these patients
accordingly.
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Limitations
It is important to examine the findings of this study in the light of its limitations. The first
limitation of the study is its generalizability. This study analyzed the administrative claims of a
Medicaid program, and the results may not be generalizable to non-Medicaid populations. The
second limitation of the study is that prescription claims were analyzed to measure medication
adherence of eligible ADHD patients. These prescription claims only provided information on
what was prescribed and dispensed to the patients; we could not identify any information or
indication on either these ADHD stimulants medication were consumed or not.
The third limitation is that a 6-month pre-index period with no prior use of ADHD
stimulant medications was used to identify patients newly started ADHD medications; however,
it is uncertain whether patients had any prior use of ADHD stimulant medications before the 6month pre-index period. The fourth limitation is that certain factors which were identified as
predictors of medication nonadherence among patients with ADHD in previous studies, such as
treatment ineffectiveness, side effects, children with a family history of ADHD, a higher level of
parental education, and lower intelligence, were unavailable in the Medicaid administrative
claims data used for this study, therefore, we were unable to examine these factors in our study.
And lastly, having an inclusion criteria of minimum of 90-day supply for an ADHD stimulant
medication might have compromised the sample size.
Conclusions
Among children/adolescents with ADHD enrolled in the Mississippi Medicaid program,
ADHD stimulant medication adherence was suboptimal, however, 12-month adherence is better
than 6-month adherence. We did not observe any significant difference in adherence when
summer break was included or excluded. Significant predictors of medication nonadherence in
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this study include having non-severe ADHD, lack of follow-ups, African – American race, and
patients residing in geographical region – 5.
Nonadherence to medication therapy can have severe consequences including but not
limited to unwanted effects, worsening of symptoms, unnecessary hospitalizations. Particularly,
patients nonadherent to ADHD medications may have difficulties in assessing the need for
medication titration and medication change. Interventions should be developed to enhance the
medication adherence among patients with ADHD. A proper understanding of the predictors of
medication nonadherence may help with the development of effective interventions and
programs focusing on predicted nonadherent subgroups to improve their adherence to prescribed
ADHD stimulant therapy, therefore the effectiveness and benefits of prescribed therapy can be
achieved.
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Appendix I: ADHD and Psychiatric Conditions ICD-9-CM Diagnosis Codes
International Classification of Disease Diagnosis Codes
ADHD
Conduct Disorders
Major Depressive
Disorder
Bipolar Disorder
Other Anxiety Disorder
Other Psychoactive
Substance Disorders

314.00, 314.01
312.00, 312.01, 312.02, 312.03, 312.81, 312.20, 312.21, 312.22, 312.23,
312.82, 313.81, 312.10, 312.11, 312.12, 312.13, 312.4, 312.89, 312.9
296.31, 296.32, 296.33, 296.34, 298.0, 296.35, 296.36, 296.30
296.40, 296.44, 296.50, 296.53, 296.60, 296.45, 296.46, 296.89, 296.7,
296.80
300.01, 300.02, 300.09, 300.00
305.80, 305.81, 305.82, 305.83, 304.60, 304.61, 304.62, 304.70, 304.71,
304.72, 304.80, 304.81, 304.82, 304.90, 304.91, 304.92
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Appendix II: List of Chronic Physical Conditions and Diagnosis Codes
Chronic Physical Conditions

ICD-9-CM Diagnosis codes

Juvenile rheumatoid arthritis

714.30, 714.31

Asthma

493.0, 493.1, 493.2, 493.8, 493.9

Epilepsy

345.0, 345.1, 345.2, 345.3, 345.4, 345.5, 345.6, 345.7, 345.8, 345.9

Diabetes mellitus

250.0, 250.1, 250.2, 250.3, 250.4, 250.5, 250.6, 250.7, 250.8, 250.9

Infantile cerebral palsy

343.0, 343.1, 343.2, 343.3, 343.4, 343.8, 343.9

Spina bifida

741.0, 741.9

Congenital anomalies

740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752,
753, 754, 755, 756, 757, 758, 759

Sickle-cell disease

282.60, 282.61, 282.62, 282.63, 282.64, 282.68, 282.69

Cystic fibrosis

277.00, 277.01, 277.02, 277.03, 277.09

Blindness and low vision

369.0, 369.1, 369.2, 369.3, 369.4, 369.6, 369.7, 369.8, 369.9

Color and night blindness

368.0, 368.1, 368.2, 368.3, 368.4, 368.5, 368.6, 368.8, 368.9

Hearing loss

389.0, 389.1, 389.2, 389.7, 389.8, 389.9

Acute lymphocytic leukemia

204.0, 204.1, 204.2, 204.8, 204.9

Acute myelogenous leukemia

205.0, 205.1, 205.2, 205.3, 205.8, 205.9

Brain tumors

191.0, 191.1, 191.2, 191.3, 191.4, 191.5, 191.6, 191.7, 191.8, 191.9

Neuroblastoma

194.0, 194.1, 194.2, 194.3, 194.4, 194.5, 194.6, 194.8, 194.9

Wilms tumor/nephroblastoma

189. 0, 189.1, 189.2, 189.3, 189.4, 189.8, 189.9

Lymphoma

200.0, 200.1, 200.2, 200.3, 200.4, 200.5, 200.6, 200.7, 200.8, 201.0,
201.1, 201.2, 201.4, 201.5, 201.6, 201.7, 201.9, 206.0, 206.1, 206.2,
206.8, 206.9

Rhabdomyosarcoma

171.0, 171.2, 171.3, 171.4, 171.5, 171.6, 171.7, 171.8, 171.9

Retinoblastoma

190.1, 190.1, 190.2, 190.3, 190.4, 190.5, 190.6, 190.7, 190.8, 190.9

Bone cancers

170.0, 170.1, 170.2, 170.3, 170.4, 170.5, 170.6, 170.7, 170.8, 170.9
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Appendix III: List of Mississippi Regions and their Counties
Mississippi Regions
Region 1
Region 2
Region 3
Region 4
Region 5
Region 6
Region 7
Region 8
Region 9

Mississippi Counties
Coahoma, Desoto, Grenada, Panola, Quitman, Tate, Tallahatchie, Tunica,
Yalobusha
Alcorn, Benton, Itawamba, Lafayette, Lee, Marshall, Pontotoc, Prentiss,
Tippah, Tishomingo, Union
Attala, Bolivar, Carroll, Holmes, Humphreys, Leflore, Montgomery,
Sunflower, Washington
Calhoun, Chickasaw, Choctaw, Clay, Lowndes, Monroe, Noxubee,
Oktibbeha, Webster, Winston
Claiborne, Copiah, Hinds, Madison, Rankin, Simpson, Sharkey, Issaquena,
Warren, Yazoo
Clarke, Jasper, Kemper, Lauderdale, Leake, Neshoba, Newton, Scott, Smith
Adams, Amite, Franklin, Jefferson, Lawrence, Lincoln, Pike, Walthall,
Wilkinson
Covington, Forrest, Greene, Jefferson Davis, Jones, Lamar, Marion, Perry,
Wayne
George, Hancock, Harrison, Jackson, Pearl River, Stone
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